Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490243 | 0.81 | AR (0.43) | KIF11PDK2PDK1PDK3PDK4 | |
| SCHEMBL92971 | 0.80 | KIF11 (0.73) | KIF11PDK2CYP4F2CYP4A11DAO | |
| SCHEMBL2636866 | 0.77 | HSD11B1 (0.42) | KIF11ARHSD11B1 | |
| SCHEMBL18999755 | 0.75 | KIF11 (0.44) | KIF11ARTRPM8HSD11B1 | |
| SCHEMBL17414243 | 0.74 | KIF11 (0.51) | KIF11PDK2CYP4F2CYP4A11DAO | |
| SCHEMBL27595825 | 0.74 | KIF11 (0.51) | KIF11PDK2ARCYP4F2CYP4A11 | |
| SCHEMBL12980946 | 0.72 | KIF11 (0.43) | KIF11CYP4F2CYP4A11RIPK1 | |
| SCHEMBL12490658 | 0.72 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL15496932 | 0.71 | AR (0.37) | KIF11ARHSD11B1 | |
| SCHEMBL12490260 | 0.71 | KIF11 (0.49) | KIF11PDK2CYP4F2CYP4A11TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| CN-103443080-B | There is the sulfonamide compounds of TRPM8 antagonistic activity | 田边三菱制药株式会社 | 2016-10-12 | — | — | CN | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2686302-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | KIF11 3307/4885PDK2 2750/4885PDK1 1876/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | KIF11 3408/4885PDK2 2641/4885PDK1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.